Mangalam Organics Limited has informed the Exchange regarding Board meeting held on February 12, 2026 for the consideration and approval of the Unaudited Standalone and Consolidated Financial Statements of the Company for the Third quarter ended December 31, 2025, which had been duly reviewed and recommended by the Audit Committee along with the Limited Review Report thereon.
MANORG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mangalam Organics' board approved Q3 FY26 results on February 12, 2026. Standalone revenue from operations rose about 22% YoY to Rs 12,244.57 lakhs, while consolidated revenue jumped roughly 33% YoY to Rs 16,429.84 lakhs. For the nine-month period, standalone profit (Total Comprehensive Income) nearly doubled to Rs 989.83 lakhs and consolidated profit surged about 166% to Rs 1,976.48 lakhs. However, Q3 standalone performance was weak on a sequential and YoY basis, with Q3 EPS falling to Rs 1.29 versus Rs 3.31 in Q3 FY25 and PBT dropping to Rs 149.82 lakhs. An exceptional item of Rs 350.60 lakhs was booked in the previous quarter (Q2 FY26). Auditor NGST & Associates issued an unqualified limited review report.
Strong 9-month revenue and profit growth is a positive, but the sharp sequential and YoY decline in Q3 standalone profits and EPS could pressure the stock in the near term. Investors should watch for explanations on the Q3 margin compression and whether the weakness is temporary or structural.